PDF Physiology of the Weight Loss Plateau after Calorie Restriction, GLP
The widespread prevalence of obesity and its adverse health effects have made sustained weight loss strategies a public health priority. While the causes of obesity are still debated,1 it is well established that a chronic positive or negative energy balance results in weight gain or loss, respectively. Caloric restriction (CR) with optimal nutrition has the potential to reverse several ...
Semaglutide versus caloric restrictioninduced weight loss
The advent of glucagon-like peptide-1 receptor agonists ( GLP -1RAs) has revolutionized obesity therapeutics, delivering weight loss far beyond what lifestyle interventions achieve. Clinical trials of a potent GLP -1RA, semaglutide, have demonstrated 10%-15% weight loss with improvements in cardio-metabolic outcomes (Drucker, 2025), fuelling adoption of GLP -1RAs as front-line pharmacotherapies ...
Mathematical modeling was used to simulate body weight trajectories, body composition, and energy balance dynamics of diet restriction , glucagon-like peptide 1 ( GLP-1 ) receptor agonism, and bariatric surgery interventions. The timing of the weight plateau was mainly determined by the intervention's ability to alter the strength of the feedback control circuit relating weight loss to increased ...
Useful Notes on Calorie Restriction And Glp 1 Receptor Internalization
Since GLP-1 RA induce a CR state, expecting it to yield entirely different body composition outcomes than what is observed in CR studies is hard to conceive. As with CR, GLP-1 RA approaches should focus on a parallel inclusion of enhanced physical activity as an essential part of the strategy to achieving optimal health in addition to weight loss.
A new tool in the arsenal The recent introduction of glucagon- like peptide- 1 ( GLP - 1 ) receptor agonists (RA), a class of widely used drugs for the treatment of T2DM, as anti- obesity medication, is posed to revolutionise the management of obesity.
To understand the concern, one must look at body composition rather than a traditional bathroom scale. When a patient loses weight through traditional caloric restriction , a portion of that loss is inevitably muscle. However, the sheer velocity of weight loss induced by GLP-1 and dual GLP-1/GIP agonists amplifies this physiological tax.
Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s ) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on ...
Integrating Diet and Physical Activity When Prescribing GLP
This Clinical Insight reviews the lifestyle factors important for patients receiving glucagon-like peptide-1 and dual receptor agonists to manage weight.
Glucagon-like peptide 1 ( GLP-1 ), a gastrointestinal peptide and central mediator of glucose metabolism, is secreted by L cells in the intestine in response to food intake. Postprandial secretion of GLP-1 is triggered by nutrient-sensing via transporters and G-protein-coupled receptors (GPCRs). GLP-1 secretion may be lower in adults with obesity/overweight (OW) or type 2 diabetes mellitus (T2DM ...
Trusted weight loss injections
Tailored nutrition guidance, mental health support, and medication monitoring included. Start with a 5-minute assessment. Doctor prescribes, medication delivered within 4 hours.
